EA201890788A1 - Препараты оланзапина с замедленным высвобождением - Google Patents

Препараты оланзапина с замедленным высвобождением

Info

Publication number
EA201890788A1
EA201890788A1 EA201890788A EA201890788A EA201890788A1 EA 201890788 A1 EA201890788 A1 EA 201890788A1 EA 201890788 A EA201890788 A EA 201890788A EA 201890788 A EA201890788 A EA 201890788A EA 201890788 A1 EA201890788 A1 EA 201890788A1
Authority
EA
Eurasian Patent Office
Prior art keywords
olanzapin
preparations
delayed delivery
methods
pharmaceutically acceptable
Prior art date
Application number
EA201890788A
Other languages
English (en)
Russian (ru)
Inventor
Марк Алан Смит
Карин Классен-Пюнт
Original Assignee
Тева Фармасьютикалз Интернэшнл Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикалз Интернэшнл Гмбх filed Critical Тева Фармасьютикалз Интернэшнл Гмбх
Publication of EA201890788A1 publication Critical patent/EA201890788A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Biological Depolymerization Polymers (AREA)
EA201890788A 2015-09-21 2016-09-21 Препараты оланзапина с замедленным высвобождением EA201890788A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562221290P 2015-09-21 2015-09-21
PCT/US2016/052757 WO2017053346A1 (en) 2015-09-21 2016-09-21 Sustained release olanzapine formulations

Publications (1)

Publication Number Publication Date
EA201890788A1 true EA201890788A1 (ru) 2018-09-28

Family

ID=57047342

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890788A EA201890788A1 (ru) 2015-09-21 2016-09-21 Препараты оланзапина с замедленным высвобождением

Country Status (21)

Country Link
US (4) US20170079985A1 (cg-RX-API-DMAC7.html)
EP (2) EP4331570A1 (cg-RX-API-DMAC7.html)
JP (2) JP2018527397A (cg-RX-API-DMAC7.html)
KR (1) KR20180054627A (cg-RX-API-DMAC7.html)
CN (2) CN116942677A (cg-RX-API-DMAC7.html)
AR (1) AR106085A1 (cg-RX-API-DMAC7.html)
AU (2) AU2016328958B2 (cg-RX-API-DMAC7.html)
CA (1) CA2998504C (cg-RX-API-DMAC7.html)
CL (1) CL2018000727A1 (cg-RX-API-DMAC7.html)
DK (1) DK3352735T3 (cg-RX-API-DMAC7.html)
EA (1) EA201890788A1 (cg-RX-API-DMAC7.html)
ES (1) ES2960753T3 (cg-RX-API-DMAC7.html)
FI (1) FI3352735T3 (cg-RX-API-DMAC7.html)
HU (1) HUE063850T2 (cg-RX-API-DMAC7.html)
IL (3) IL295161A (cg-RX-API-DMAC7.html)
MX (2) MX2018003380A (cg-RX-API-DMAC7.html)
NZ (1) NZ740665A (cg-RX-API-DMAC7.html)
PL (1) PL3352735T3 (cg-RX-API-DMAC7.html)
PT (1) PT3352735T (cg-RX-API-DMAC7.html)
TW (1) TWI798161B (cg-RX-API-DMAC7.html)
WO (1) WO2017053346A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018172850A1 (en) * 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
CN111836615A (zh) * 2018-01-05 2020-10-27 英倍尔药业股份有限公司 通过精密鼻装置的奥氮平的鼻内递送
AU2020410549A1 (en) * 2019-12-20 2022-04-14 Alar Pharmaceuticals Inc. Long-acting injectable formulations of ketamine pamoate salts
CN112587505A (zh) * 2020-10-16 2021-04-02 长春斯菲尔生物科技有限公司 一种奥氮平双羟萘酸盐缓释微粒制剂及其制备方法
WO2025188992A1 (en) * 2024-03-06 2025-09-12 Neurelis, Inc. Oral film for rapid active delivery

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
EA002825B1 (ru) * 1997-09-30 2002-10-31 Эли Лилли Энд Компани Препарат 2-метилтиенобензодиазепина
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DK1635875T3 (da) 2003-06-26 2009-01-12 Psivida Inc In-situ-geldannende lægemiddeladministrationssystem
KR101242486B1 (ko) 2004-01-12 2013-03-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 장기 전달을 위한 제형 및 그의 이용 방법
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
NL1026261C2 (nl) 2004-05-25 2005-11-28 Nanomi B V Sproei inrichting met een nozzleplaat voorzien van structuren ter bevordering van self-breakup, een nozzleplaat, alsmede werkwijzen ter vervaardiging en toepassing van een dergelijke nozzleplaat.
NZ551990A (en) 2004-06-04 2011-01-28 Camurus Ab Liquid depot formulations
AU2005307797B2 (en) * 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
EP1874267A1 (en) * 2005-04-13 2008-01-09 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
WO2006109183A1 (en) * 2005-04-13 2006-10-19 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
ATE552032T1 (de) * 2005-07-14 2012-04-15 Lithera Inc Verbesserte lipolytikum-formulierung mit hinhaltender wirkstofffreigabe für die arealbehandlung von fettgewebe
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
WO2007139744A2 (en) 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
KR20140109509A (ko) 2006-07-11 2014-09-15 큐피에스 엘엘씨 펩타이드의 지속 방출 전달을 위한 의약 조성물
FI20070174A0 (fi) 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
EP2139458A4 (en) 2007-04-19 2013-01-23 Dong A Pharm Co Ltd COMPOSITION OF BIODEGRADABLE MICROSPHERES WITH CONTROLLED RELEASE OF A GLUCOSE REGULATING PEPTIDE AND RELATED FORMULA
US10010612B2 (en) 2007-05-25 2018-07-03 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
ES2324009B1 (es) 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
JP5222550B2 (ja) * 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US20090263443A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedics, Inc. Methods for treating post-operative effects such as spasticity and shivering with clondine
EP2309982A2 (en) 2008-06-03 2011-04-20 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
KR101626632B1 (ko) 2008-08-12 2016-06-01 노파르티스 아게 제약 조성물
PT2355853T (pt) 2008-10-10 2017-03-15 Polyactiva Pty Ltd Conjugados polímero biodegradável ¿ unidade bioativa
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
US9561352B2 (en) 2009-03-12 2017-02-07 Delpor, Inc. Implantable device for long-term delivery of drugs
EP2485712A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Subcutaneous paliperidone composition
DK3536333T3 (da) 2010-01-04 2022-10-24 Mapi Pharma Ltd Depotsystem der omfatter glatirameracetat
EP2343046A1 (en) 2010-01-08 2011-07-13 Nirvana's Tree House B.V. Functionalised triblock copolymers and compositions containing such polymers
LT2394663T (lt) * 2010-05-31 2022-02-10 Laboratorios Farmaceuticos Rovi, S.A. Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
FR2968994B1 (fr) 2010-12-17 2012-12-28 Flamel Tech Sa Procede de preparation de nanoparticules
CN103491946B (zh) 2010-12-29 2016-08-10 美蒂森 可生物降解的药物释放组合物
SI2717914T1 (sl) 2011-06-10 2020-07-31 Ramscor Inc. Formulacije z zadržanim sproščanjem za dostavo proteinov v oko in postopki njihove priprave
MX350469B (es) 2011-10-24 2017-09-07 Endo Pharmaceuticals Solutions Composiciones para el suministro de farmacos implantables y metodos para su tratamiento.
MX364864B (es) 2012-01-23 2019-05-09 Allergan Inc Microesferas o microparticulas biodegradables o bioerosionables de liberacion progresiva suspendidas en una formulacion de farmaco inyectable de formacion de deposito solidificante.
CN103417492A (zh) * 2012-05-25 2013-12-04 上海现代药物制剂工程研究中心有限公司 含有奥氮平的生物降解微球制剂及其制备方法
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
WO2014202214A1 (en) 2013-06-20 2014-12-24 Pharmathen S.A. Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile
CN103877005A (zh) * 2014-03-26 2014-06-25 陈德香 一种复方奥氮平皮下埋植缓释剂

Also Published As

Publication number Publication date
AU2016328958A1 (en) 2018-04-05
US20180264001A1 (en) 2018-09-20
US20240238307A1 (en) 2024-07-18
HUE063850T2 (hu) 2024-02-28
MX2018003380A (es) 2018-08-16
AU2016328958B2 (en) 2022-04-21
DK3352735T3 (da) 2023-10-30
IL258086A (en) 2018-05-31
FI3352735T3 (fi) 2023-10-20
JP2018527397A (ja) 2018-09-20
AU2022206695A1 (en) 2022-08-11
PT3352735T (pt) 2023-10-30
US20220323458A1 (en) 2022-10-13
EP4331570A1 (en) 2024-03-06
US20170079985A1 (en) 2017-03-23
KR20180054627A (ko) 2018-05-24
AR106085A1 (es) 2017-12-13
WO2017053346A1 (en) 2017-03-30
JP2021167331A (ja) 2021-10-21
IL295161A (en) 2022-09-01
TW201726144A (zh) 2017-08-01
TWI798161B (zh) 2023-04-11
CA2998504A1 (en) 2017-03-30
PL3352735T3 (pl) 2024-01-29
CA2998504C (en) 2023-06-20
EP3352735A1 (en) 2018-08-01
MX2022007315A (es) 2022-07-13
HK1255946A1 (en) 2019-09-06
CN116942677A (zh) 2023-10-27
CN108289834A (zh) 2018-07-17
IL275735A (en) 2020-08-31
NZ740665A (en) 2023-04-28
EP3352735B1 (en) 2023-08-30
CL2018000727A1 (es) 2018-09-28
ES2960753T3 (es) 2024-03-06

Similar Documents

Publication Publication Date Title
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
PH12016500582B1 (en) Heterocyclic compounds and uses thereof
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
EA201890731A1 (ru) Модуляторы корового белка гепатита b
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201790932A1 (ru) Дозировка и введение нефукозилированных анти-cd40 антител
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
JO3735B1 (ar) مركبات ألكين بها استبدال رباعي واستخداماتها
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
MD3416631T2 (ro) Agenți terapeutici pentru bolile neurodegenerative
MX389354B (es) Macrociclos peptidomimeticos y formulaciones de los mismos.
NZ760790A (en) Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
EA201992832A1 (ru) Подкожное введение adamts13
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
MX2022007315A (es) Formulaciones de olanzapina de liberacion sostenida.
CY1123469T1 (el) Σχηματα δοσολογιας του melflufen για καρκινο
EA201691741A1 (ru) Фармацевтическая композиция
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
EA201790991A1 (ru) Способ лечения с использованием пегилированного интерферона
MD4763B1 (ro) Compoziţie farmaceutică
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically